Trimetazidine inhibits liver fibrosis and hepatic stellate cell proliferation and blocks transforming growth factor-β (TGFβ)/Smad signaling in vitro and in vivo

Trimetazidine (TMZ) has been used extensively to treat coronary artery disease and to reduce fibrosis. Liver fibrosis is a reversible process. However, the impacts of TMZ on liver fibrosis triggered by CCl(4) and on hepatic stellate cells in liver fibrosis remain to be elaborated. In the current stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Wenwen, Zhou, Danhua, Zhang, Shimeng, Qian, Jiaping, Yang, Lingxia, Tang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973947/
https://www.ncbi.nlm.nih.gov/pubmed/35249457
http://dx.doi.org/10.1080/21655979.2022.2047403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973947/
https://www.ncbi.nlm.nih.gov/pubmed/35249457
http://dx.doi.org/10.1080/21655979.2022.2047403

Ejemplares similares